NHI coverage extension for Zelmac in combined therapy.

The NHI reimbursement seems to be extended to a combination therapy of Zelmac with other antispasmodics and GIT regulator drugs.

Novartis Korea said that Zelmac (tagaserod hydrogen maleate) was a first and unique drug for the treatment of irritable bowel syndrome (IBS) approved by the U. S. FDA, and the NHI reimbursement was approved even in combination therapy of Zelmac with other drugs s...